| DC Field | Value | Language |
|---|
| dc.contributor.author | Borozdina, N. A. | - |
| dc.contributor.author | Kazakova, E. N. | - |
| dc.contributor.author | Gladkikh, I. N. | - |
| dc.contributor.author | Leychenko, E. V. | - |
| dc.contributor.author | Dyachenko, I. A. | - |
| dc.date.accessioned | 2024-08-23T07:42:30Z | - |
| dc.date.available | 2024-08-23T07:42:30Z | - |
| dc.date.issued | 2024 | - |
| dc.identifier.citation | Long-term administration of the α-amylase inhibitor acarbose effective against type 2 diabetes symptoms in C57BL/6 mice / N.A. Borozdina, E.N. Kazakova, I.N. Gladkikh [et al.] // Research Results in Pharmacology. - 2024. - Vol.10, №2.-P. 65-72. - Doi: 10.18413/rrpharmacology.10.455. - Refer.: p. 71. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/63417 | - |
| dc.description.abstract | α-amylase inhibitors are an important class of second-line antihyperglycemic drugs. They slow down the breakdown and absorption of carbohydrates, reducing peak glucose concentration with meals. Recent reports have also shown other beneficial effects of α-amylase inhibitors on type 2 diabetes mellitus (T2DM) | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | acarbose | ru |
| dc.subject | α-amylase inhibitors | ru |
| dc.subject | insulin | ru |
| dc.subject | type 2 diabetes mellitus | ru |
| dc.subject | C57BL/6 mice | ru |
| dc.title | Long-term administration of the α-amylase inhibitor acarbose effective against type 2 diabetes symptoms in C57BL/6 mice | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 10, № 2
|
